Jimenez R E, Z'graggen K, Hartwig W, Graeme-Cook F, Warshaw A L, Fernandez-del Castillo C
Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114, USA.
Am J Pathol. 1999 Apr;154(4):1223-9. doi: 10.1016/S0002-9440(10)65374-6.
Dimethylbenzanthracene (DMBA) induces pancreatic adenocarcinomas in rats 9 months after carcinogen exposure, with precursor lesions (tubular complexes) developing 1 month after initiation of treatment. Because previous studies have suggested an acinar cell of origin for these tumors, we investigated the expression pattern of ductal, acinar, and islet cell markers in these cancers to gain insight into their phenotype and cell of origin. Pancreatic neoplasms were induced in rats by implantation of DMBA into the head of the pancreas. Lesions studied included 10 early tubular complexes (DMBA for 2 weeks), 8 tubular complexes (DMBA for 1 month), and 10 adenocarcinomas (DMBA for 9 months). Normal rat pancreas served as a control. For comparison, 5 human ductal adenocarcinomas were also evaluated. Immunohistochemistry with ductal (keratin, cytokeratin 19, cytokeratin 20), acinar (chymotrypsin), and islet (chromogranin A) cell markers was performed to analyze the tissues. Rat tubular complexes and adenocarcinomas revealed strong expression of keratin, cytokeratin 19, and cytokeratin 20 in the cytoplasm of all neoplastic cells, absence of chymotrypsin, and rare immunoreactivity to chromogranin A. Human adenocarcinomas showed strong expression of keratin and cytokeratin 19 in all neoplastic cells, expression of cytokeratin 20 in 5-20% of cells, and absence of chymotrypsin and chromogranin A. Pancreatic adenocarcinomas induced by DMBA in rats express markers consistent with a ductal phenotype, as observed in human tumors. Ductal marker expression in early tumor stages suggests a ductal cell of origin.
二甲基苯并蒽(DMBA)在致癌剂暴露9个月后可诱导大鼠发生胰腺腺癌,治疗开始1个月后会出现前体病变(管状复合体)。由于先前的研究表明这些肿瘤起源于腺泡细胞,我们研究了这些癌症中导管、腺泡和胰岛细胞标志物的表达模式,以深入了解它们的表型和起源细胞。通过将DMBA植入大鼠胰腺头部来诱导胰腺肿瘤。研究的病变包括10个早期管状复合体(DMBA处理2周)、8个管状复合体(DMBA处理1个月)和10个腺癌(DMBA处理9个月)。正常大鼠胰腺作为对照。为作比较,还评估了5例人导管腺癌。采用导管(角蛋白、细胞角蛋白19、细胞角蛋白20)、腺泡(胰凝乳蛋白酶)和胰岛(嗜铬粒蛋白A)细胞标志物进行免疫组织化学分析组织。大鼠管状复合体和腺癌显示所有肿瘤细胞胞质中角蛋白、细胞角蛋白19和细胞角蛋白20呈强表达,胰凝乳蛋白酶缺失,对嗜铬粒蛋白A的免疫反应罕见。人腺癌显示所有肿瘤细胞中角蛋白和细胞角蛋白19呈强表达,5%-20%的细胞表达细胞角蛋白20,且胰凝乳蛋白酶和嗜铬粒蛋白A缺失。DMBA诱导的大鼠胰腺腺癌表达与导管表型一致的标志物,如在人类肿瘤中所见。早期肿瘤阶段的导管标志物表达提示起源于导管细胞。